InvivydIVVD
IVVD
About: Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Employees: 100
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
228% more call options, than puts
Call options by funds: $118K | Put options by funds: $36K
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
25% more capital invested
Capital invested by funds: $34M [Q4 2024] → $42.6M (+$8.62M) [Q1 2025]
4% more funds holding
Funds holding: 77 [Q4 2024] → 80 (+3) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
5.48% less ownership
Funds ownership: 64.19% [Q4 2024] → 58.71% (-5.48%) [Q1 2025]
16% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 25
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
531%
upside
Avg. target
$7
784%
upside
High target
$9
1,036%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio | 531%upside $5 | Buy Maintained | 28 May 2025 |
D. Boral Capital Jason Kolbert | 1,036%upside $9 | Buy Maintained | 16 May 2025 |
Financial journalist opinion
Based on 3 articles about IVVD published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus
WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that results from its CANOPY Phase 3 clinical trial of pemivibart have been published online as an Advance Article in the peer-reviewed journal Clinical Infectious Diseases (CID), available here. The publication, titled “Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)” highlights attractive safety, substantial clinical antiviral activity, the immunobridge between calculated serum virus neutralizing antibody (sVNA) titers and pemivibart and historical clinical efficacy data, and nominally statistically significant and clinically meaningful efficacy of pemivibart versus placebo in a contemporary U.S. population facing, immune-evasive Omicron SARS-CoV-2 viruses.
Neutral
GlobeNewsWire
3 weeks ago
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. NCCN joins the Infectious Disease Society of America (IDSA) that updated its COVID-19 guidelines in August 2024 to recommend the use of PEMGARDA (pemivibart) for pre-exposure prophylaxis (PrEP) in moderately to severely immunocompromised adults and adolescents (aged 12 or older) at risk for progression to severe COVID-19 when predominant regional variants are susceptible to pemivibart.
Neutral
GlobeNewsWire
3 weeks ago
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by the Agency generally aligns with recent Invivyd Citizen Petition requests In contrast to vaccine boosters, monoclonal antibody (mAb) therapies, including pemivibart, underwent contemporary randomized, placebo-controlled trials to evaluate safety, immunogenicity, and exploratory efficacy in relevant, modern Americans, against relevant, modern immune-evasive SARS-CoV-2 viruses, and over the long-term Invivyd plans to advance next generation COVID-19 mAbs to improve product scalability and system-friendliness while preserving strong anticipated mAb preventative efficacy; additional data on Invivyd's investigational mAb VYD2311 expected this quarter Invivyd plans to engage FDA shortly on an expedited pathway to develop high-quality, scalable COVID-19 prevention and treatment options urgently needed by high-risk populations identified by the FDA WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today commends new U.S. Food and Drug Administration (FDA) leadership on taking important steps to acknowledge and resolve the significant uncertainty surrounding the contemporary COVID-19 vaccine booster efficacy landscape.
Neutral
Seeking Alpha
1 month ago
Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript
Invivyd, Inc. (NASDAQ:IVVD ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Katie Falzone - Senior Vice President, Finance Marc Elia - Chairman Tim Lee - Chief Commercial Officer Bill Duke - Chief Financial Officer Dr. Robert Allen - Chief Scientific Officer Dr. Mark Wingertzahn - Senior Vice President, Clinical Development Conference Call Participants Kyle Yang - Jefferies Luis Santos - H.C. Wainwright Operator Thank you for standing by.
Negative
Zacks Investment Research
1 month ago
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.38 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
WALTHAM, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended March 31, 2025, and provided recent business highlights.
Neutral
GlobeNewsWire
1 month ago
Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy
WALTHAM, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has submitted a Citizen Petition with the U.S. Food and Drug Administration (FDA) calling on the Agency to evolve from historical approaches to the development of vaccines and monoclonal antibodies (mAbs) for COVID-19 prevention, in order to rebuild American's trust in scientific data, public health recommendations, and preventatives, including mAbs and vaccines, when effective. Americans will need a robust arsenal to manage COVID-19 and other viral infectious disease for decades to come.
Neutral
GlobeNewsWire
1 month ago
Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025, at 11:00 a.m. ET in New York, NY.
Neutral
GlobeNewsWire
1 month ago
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has initiated a discovery program for a measles monoclonal antibody (mAb). Multiple healthcare providers (HCPs) who are treating active measles and monitoring contacts and outbreaks have inquired directly to Invivyd about the possibility of accessing such a medicine, as there are no currently approved therapies for measles or for post-exposure prophylaxis. Measles monoclonal neutralizing antibody discovery efforts would join current Invivyd discovery programs for next-generation COVID-19, respiratory syncytial virus (RSV), and influenza mAbs designed to treat acute infection or provide a high-quality alternative to vaccination.
Neutral
GlobeNewsWire
1 month ago
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, 2025, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and provide recent business highlights.
Charts implemented using Lightweight Charts™